Number: 201202090 Principal Investigator: Hawkins, William
Title: A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Phase: II Disease Site: Pancreas
Participating Site(s):
Main Campus
Map and Directions
Contact: 800-600-3606 or

The purpose of this study is to test the effectiveness and safety of GS-6624 at different dose levels. GS-6624 is an experimental agent being developed to treat many different diseases including
myelofibrosis. The enzyme LOXL2 (a small protein found in the body) is important in the growth and spread of cancer cells as it helps the supporting tissue around the cells to grow. GS-6624 is an antibody, which is a Y-shaped protein that selectively binds to LOXL2, and in doing so causes changes in the supporting tissue which leads to destruction of the cancer cells. Therefore, GS-6624
stops the growth and spread of cancer cells.
More Information: Entry
Internal Protocol Documents (requires Siteman administrative database password)